Literature DB >> 9399961

B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.

D A Frank1, S Mahajan, J Ritz.   

Abstract

To explore the pathogenesis of chronic lymphocytic leukemia (CLL), we examined whether phosphorylation of one or more signal transducer and activator of transcription (STAT) factors was abnormal in cells from CLL patients. No constitutive tyrosine phosphorylation was detected on any STAT in CLL cells. To assess the phosphorylation of serine residues of STAT1 and STAT3 in CLL cells, we raised antibodies that specifically recognize the form of STAT1 phosphorylated on ser-727 and the form of STAT3 phosphorylated on ser-727. We found that in 100% of patients with CLL (n = 32), STAT1 and STAT3 were constitutively phosphorylated on serine. This was in contrast to normal peripheral blood B lymphocytes or CD5+) B cells isolated from tonsils, in which this phosphorylation was absent. Serine phosphorylation of STAT1 and STAT3 was seen occasionally in other leukemias, but it was a universal finding only in CLL. The serine phosphorylation of these STATs was a continuous process, as incubation of CLL cells with the kinase inhibitor H7 led to the dephosphorylation of these serine residues. The STAT serine kinase in CLL cells has not been identified, and appears to be neither mitogen-activated protein kinase nor pp70(s6k). In summary, the constitutive serine phosphorylation of STAT1 and STAT3 is present in all CLL samples tested to date, although the physiologic significance of this modification remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399961      PMCID: PMC508527          DOI: 10.1172/JCI119869

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

Review 1.  Structure, expression, and regulation of protein kinases involved in the phosphorylation of ribosomal protein S6.

Authors:  R L Erikson
Journal:  J Biol Chem       Date:  1991-04-05       Impact factor: 5.157

2.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.

Authors:  G Q Daley; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

3.  Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics.

Authors:  C Bialojan; A Takai
Journal:  Biochem J       Date:  1988-11-15       Impact factor: 3.857

4.  Identification of substrate recognition determinants for human ERK1 and ERK2 protein kinases.

Authors:  F A Gonzalez; D L Raden; R J Davis
Journal:  J Biol Chem       Date:  1991-11-25       Impact factor: 5.157

5.  Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase.

Authors:  D J Price; J R Grove; V Calvo; J Avruch; B E Bierer
Journal:  Science       Date:  1992-08-14       Impact factor: 47.728

6.  Definition of a consensus sequence for peptide substrate recognition by p44mpk, the meiosis-activated myelin basic protein kinase.

Authors:  I Clark-Lewis; J S Sanghera; S L Pelech
Journal:  J Biol Chem       Date:  1991-08-15       Impact factor: 5.157

7.  Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C.

Authors:  H Hidaka; M Inagaki; S Kawamoto; Y Sasaki
Journal:  Biochemistry       Date:  1984-10-09       Impact factor: 3.162

Review 8.  Interleukin-2: inception, impact, and implications.

Authors:  K A Smith
Journal:  Science       Date:  1988-05-27       Impact factor: 47.728

9.  Regulation of B-cell growth and immunoglobulin gene transcription by interleukin-6.

Authors:  J E Tanner; G Tosato
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

10.  Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases.

Authors:  J Chung; C J Kuo; G R Crabtree; J Blenis
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

View more
  87 in total

1.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Authors:  Lauren L C Marotta; Vanessa Almendro; Andriy Marusyk; Michail Shipitsin; Janina Schemme; Sarah R Walker; Noga Bloushtain-Qimron; Jessica J Kim; Sibgat A Choudhury; Reo Maruyama; Zhenhua Wu; Mithat Gönen; Laura A Mulvey; Marina O Bessarabova; Sung Jin Huh; Serena J Silver; So Young Kim; So Yeon Park; Hee Eun Lee; Karen S Anderson; Andrea L Richardson; Tatiana Nikolskaya; Yuri Nikolsky; X Shirley Liu; David E Root; William C Hahn; David A Frank; Kornelia Polyak
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

3.  Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.

Authors:  Katrin Friedbichler; Marc A Kerenyi; Boris Kovacic; Geqiang Li; Andrea Hoelbl; Saliha Yahiaoui; Veronika Sexl; Ernst W Müllner; Sabine Fajmann; Sabine Cerny-Reiterer; Peter Valent; Hartmut Beug; Fabrice Gouilleux; Kevin D Bunting; Richard Moriggl
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

4.  Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.

Authors:  Xueqing Liang; E Ashley Moseman; Michael A Farrar; Veronika Bachanova; Daniel J Weisdorf; Bruce R Blazar; Wei Chen
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

Review 5.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 6.  The molecular details of cytokine signaling via the JAK/STAT pathway.

Authors:  Rhiannon Morris; Nadia J Kershaw; Jeffrey J Babon
Journal:  Protein Sci       Date:  2018-12       Impact factor: 6.725

7.  Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Ivo Veletic; Alessandra Ferrajoli; Jan Burger; Philip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Int J Cancer       Date:  2017-08-04       Impact factor: 7.396

8.  TYK2 is a key regulator of the surveillance of B lymphoid tumors.

Authors:  Dagmar Stoiber; Boris Kovacic; Christian Schuster; Carola Schellack; Marina Karaghiosoff; Rita Kreibich; Eva Weisz; Michaela Artwohl; Olaf C Kleine; Mathias Muller; Sabina Baumgartner-Parzer; Jacques Ghysdael; Michael Freissmuth; Veronika Sexl
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

9.  Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

Authors:  Erik A Nelson; Sarah R Walker; Alicia Kepich; Laurie B Gashin; Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Kenneth C Anderson; David A Frank
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

10.  Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.

Authors:  Ping Li; David Harris; Zhiming Liu; Jie Liu; Michael Keating; Zeev Estrov
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.